Yogesh Agrawal, MD of Ajanta Pharma outlined Ajanta Pharma’s strategy to capitalise on the opportunity through its ...

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...

Under the agreement, Biocon will supply semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive ...

Mumbai-based Ajanta Pharma has entered into an agreement with Biocon to commercialise its version of semaglutide across ...

Under the agreement, Biocon will supply semaglutide to Ajanta Pharma for exclusive marketing in 23 countries Shares of Ajanta ...

Ajanta Pharma has signed an in-licensing pact with Biocon to commercialise semaglutide in 26 countries across Africa, the ...

Semalutide improves glycaemic control in adults. The product patent expires in most these markets in March 2026. Ajanta ...

Biocon will supply Semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in three countries across Africa, West Asia, and Central Asia ...

Hindustan Copper hits new high, Tata Capital settles SEBI case, Ola Electric and Ajanta Pharma in focus amid a flat market ...

Emcure Pharmaceuticals has informed the exchanges that the United States Food and Drug Administration (USFDA) has issued a No ...